Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Filings indexed 678 across all filing types
Latest filing 2025-03-31 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Regulatory Filings
2025-03-31 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window pursuant to insider trading regulations. It mentions the upcoming declaration of audited financial results but does not contain any financial data or the results themselves. The document is short (1516 characters) and serves as a notification rather than a report. Therefore, it is an announcement related to regulatory compliance and trading restrictions, fitting best under Regulatory Filings (RNS).
2025-03-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain any financial data, report content, or detailed presentation materials. The document is short (1766 characters) and serves as an announcement of scheduled meetings rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-24 English
Updates
Board/Management Information Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the adoption of an Employee Stock Option Scheme (ESOP Scheme 2025). It provides clarifications on the performance metrics for vesting and the authority of the committee to accelerate vesting. The content is focused on corporate governance and employee compensation plans rather than financial results, audit, or regulatory compliance filings. It is not a full report but an announcement or clarification related to a corporate governance matter. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest specific category is 'Board/Management Information (MANG)' since it relates to management decisions and schemes affecting employees and executives. Therefore, the document is best classified as Board/Management Information (MANG).
2025-03-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which mandates disclosure of material events including investor meetings. The content is an announcement of upcoming meetings rather than a financial report, earnings release, or detailed investor presentation. The document length is short (1715 characters) and it serves as an informational notice about scheduled meetings with investors and analysts. This fits the category of Capital/Financing Update (CAP) as it relates to investor relations and scheduled meetings, which are typically disclosed under this category. It is not a full investor presentation (IP) or earnings release (ER), nor is it a regulatory filing (RNS) or report publication announcement (RPA).
2025-03-11 English
Shareholders meeting
Regulatory Filings
2025-03-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.